Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer
Open Access
- 16 May 2017
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 42 (4), 302-310
- https://doi.org/10.1080/07435800.2017.1319858
Abstract
Purpose: Differentiated thyroid cancer is the most common endocrine malignancy. Recurrences (5–20%) are the main reason for follow-up. Thyroglobulin (Tg) has proven to be an excellent disease marker, but thyroglobulin-antibodies (Tg-Ab) may interfere with Tg measurement, leading to over or underestimation. It is proposed that the Tg-Ab trend can be used as a marker for disease recurrence, yet few studies define trend and have a long-term follow-up. The objective of our study was to investigate the value of a well-defined Tg-Ab trend as a surrogate marker for disease recurrence during long-term follow-up. Methods: We retrospectively studied patients treated at the Nuclear Department of the University Medical Center Utrecht from 1998 to 2010 and the Netherlands Cancer Institute from 2000 to 2009. All patients with Tg-Ab 12 months after treatment were included. The definition of a rise was >50% increase of the Tg-Ab value in a 2 year time period. A decline as >50% decrease of the Tg-Ab value. Results: Twenty-five patients were included. None of the patients with declining or stable Tg-Ab without a concomitant rise in Tg developed a recurrence. Four patients did suffer a recurrence. Three of these patients had a rising Tg-Ab trend, in two of these patients Tg was undetectable. Conclusions: Tg-Ab trend can be used as a crude surrogate marker for long-term follow-up of Tg-Ab patients. A rising trend in Tg-Ab warrants further investigation to detect recurrent disease. Stable or declining Tg-Ab levels do not seem to reflect a risk for recurrence.Keywords
This publication has 24 references indexed in Scilit:
- DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paperActa Endocrinologica, 2014
- Sequential Changes of Serum Antithyroglobulin Antibody Levels Are a Good Predictor of Disease Activity in Thyroglobulin-Negative Patients with Papillary Thyroid CarcinomaThyroid®, 2014
- Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancerClinical Endocrinology, 2014
- Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.Journal of Clinical Endocrinology & Metabolism, 2013
- Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using18F-FDG PET/CTClinical Endocrinology, 2010
- Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2008
- Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 2005
- Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomyActa Endocrinologica, 2005
- Serum Thyroglobulin Autoantibodies: Prevalence, Influence on Serum Thyroglobulin Measurement, and Prognostic Significance in Patients with Differentiated Thyroid Carcinoma1Journal of Clinical Endocrinology & Metabolism, 1998
- Papillary and Follicular Thyroid CarcinomaThe New England Journal of Medicine, 1998